John Dawson awarded CBE in the Queen’s New Year Honours List

4 January 2022

Oxford, UK – 31 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that the Group’s Chief Executive Officer John Dawson has been awarded a CBE (Commander of the Order of the British Empire) for services to UK Life Science as part of the Queen’s New Year Honours List.

Dr. Roch Doliveux, Chair of Oxford Biomedica, said: “I warmly congratulate John for receiving this thoroughly deserved recognition. Thanks to his foresight, Oxford Biomedica has grown to become a world leader in cell and gene therapy, helping society during the COVID-19 pandemic and beyond. I and the entire Board are extremely grateful to John for his warm and resilient leadership and having built Oxford Biomedica as a world leader in viral vectors for cell and gene therapy, enabling so many lives to be saved.”


Oxford Biomedica plc: T: +44 (0)1865 783 000 / E:
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal

About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim and Arcellx, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at